Feasibility of administering anti-CD45 iodine ((131)I) apamistamab [Iomab-B] for re-induction and targeted conditioning in older patients with active, relapsed or refractory AML without lead-lined rooms: SIERRA trial experience at MSKCC Meeting Abstract

  

Authors:	Chu, B. P.; Pandit-Taskar, N.; Gyurkocza, B.; Liang, Q.; Miodownik, D.; Reddy, V.; Berger, M. S.; Dauer, L. T.
Abstract Title:	Feasibility of administering anti-CD45 iodine ((131)I) apamistamab [Iomab-B] for re-induction and targeted conditioning in older patients with active, relapsed or refractory AML without lead-lined rooms: SIERRA trial experience at MSKCC
Meeting Title:	61st Annual Meeting and Exposition of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	134
Issue:	Suppl. 1
Meeting Dates:	2019 Dec 7-10
Meeting Location:	Orlando, FL
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2019-11-13
Language:	English
ACCESSION:	WOS:000577164607228
DOI:	10.1182/blood-2019-131230
PROVIDER:	wos
Notes:	Meeting Abstract: 5839 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/175629